Literature DB >> 28927790

Design, semisynthesis and potent cytotoxic activity of novel 10-fluorocamptothecin derivatives.

Cheng-Jie Yang1, Zi-Long Song1, Masuo Goto2, Pei-Ling Hsu2, Xiao-Shuai Zhang1, Qian-Ru Yang1, Ying-Qian Liu3, Mei-Juan Wang1, Susan L Morris-Natschke2, Xiao-Fei Shang1, Kuo-Hsiung Lee4.   

Abstract

Fluorination is a well-known strategy for improving the bioavailability of bioactive molecules in the lead optimization phase of drug discovery projects. In an attempt to improve the antitumor activity of camptothecins (CPTs), novel 10-fluoro-CPT derivatives were designed, synthesized and evaluated for cytotoxicity against five human cancer cell lines (A-549, MDA-MB-231, KB, KB-VIN and MCF-7). All of the derivatives showed more potent in vitro cytotoxic activity than the clinical CPT-derived drug irinotecan against the tumor cell lines tested, and most of them showed comparable or superior potency to topotecan. Remarkably, compounds 16b (IC50, 67.0nM) and 19b (IC50, 99.2nM) displayed the highest cytotoxicity against the multidrug-resistant (MDR) KB-VIN cell line and merit further development as preclinical drug candidates for treating cancer, including MDR phenotype. Our study suggested that incorporation of a fluorine atom into position 10 of CPT is an effective method for discovering new potent CPT derivatives.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Camptothecin; Cytotoxic activity; Fluorination; Synthesis

Mesh:

Substances:

Year:  2017        PMID: 28927790      PMCID: PMC5831374          DOI: 10.1016/j.bmcl.2017.09.012

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  22 in total

Review 1.  Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II-III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas.

Authors:  Yu Zhou; Jiang Wang; Zhanni Gu; Shuni Wang; Wei Zhu; José Luis Aceña; Vadim A Soloshonok; Kunisuke Izawa; Hong Liu
Journal:  Chem Rev       Date:  2016-01-12       Impact factor: 60.622

Review 2.  Monofluorination of Organic Compounds: 10 Years of Innovation.

Authors:  Pier Alexandre Champagne; Justine Desroches; Jean-Denys Hamel; Mathilde Vandamme; Jean-François Paquin
Journal:  Chem Rev       Date:  2015-04-09       Impact factor: 60.622

3.  Suzuki coupling based synthesis and in vitro cytotoxic evaluation of 7-heteroaryl-substituted camptothecin analogs.

Authors:  Lei Wang; Ying Huang; Jie Zhang; Linjiang Tong; Yi Chen; Wei Lu; Qingqing Huang
Journal:  Bioorg Med Chem Lett       Date:  2014-01-29       Impact factor: 2.823

4.  Novel 7-oxyiminomethyl derivatives of camptothecin with potent in vitro and in vivo antitumor activity.

Authors:  S Dallavalle; A Ferrari; B Biasotti; L Merlini; S Penco; G Gallo; M Marzi; M O Tinti; R Martinelli; C Pisano; P Carminati; N Carenini; G Beretta; P Perego; M De Cesare; G Pratesi; F Zunino
Journal:  J Med Chem       Date:  2001-09-27       Impact factor: 7.446

5.  Novel cytotoxic 7-iminomethyl and 7-aminomethyl derivatives of camptothecin.

Authors:  S Dallavalle; A Ferrari; L Merlini; S Penco; N Carenini; M De Cesare; P Perego; G Pratesi; F Zunino
Journal:  Bioorg Med Chem Lett       Date:  2001-02-12       Impact factor: 2.823

6.  Alkyl esters of camptothecin and 9-nitrocamptothecin: synthesis, in vitro pharmacokinetics, toxicity, and antitumor activity.

Authors:  Z Cao; N Harris; A Kozielski; D Vardeman; J S Stehlin; B Giovanella
Journal:  J Med Chem       Date:  1998-01-01       Impact factor: 7.446

7.  New colorimetric cytotoxicity assay for anticancer-drug screening.

Authors:  P Skehan; R Storeng; D Scudiero; A Monks; J McMahon; D Vistica; J T Warren; H Bokesch; S Kenney; M R Boyd
Journal:  J Natl Cancer Inst       Date:  1990-07-04       Impact factor: 13.506

8.  Design, synthesis, cytotoxic activity and molecular docking studies of new 20(S)-sulfonylamidine camptothecin derivatives.

Authors:  Zi-Long Song; Mei-Juan Wang; Lanlan Li; Dan Wu; Yu-Han Wang; Li-Ting Yan; Susan L Morris-Natschke; Ying-Qian Liu; Yong-Long Zhao; Chih-Ya Wang; Huanxiang Liu; Masuo Goto; Heng Liu; Gao-Xiang Zhu; Kuo-Hsiung Lee
Journal:  Eur J Med Chem       Date:  2016-03-03       Impact factor: 6.514

9.  A new strategy to improve the metabolic stability of lactone: discovery of (20S,21S)-21-fluorocamptothecins as novel, hydrolytically stable topoisomerase I inhibitors.

Authors:  Zhenyuan Miao; Lingjian Zhu; Guoqiang Dong; Chunlin Zhuang; Yuelin Wu; Shengzheng Wang; Zizao Guo; Yang Liu; Shanchao Wu; Shiping Zhu; Kun Fang; Jianzhong Yao; Jian Li; Chunquan Sheng; Wannian Zhang
Journal:  J Med Chem       Date:  2013-10-09       Impact factor: 7.446

10.  Preclinical profile of antitumor activity of a novel hydrophilic camptothecin, ST1968.

Authors:  Claudio Pisano; Michelandrea De Cesare; Giovanni Luca Beretta; Valentina Zuco; Graziella Pratesi; Sergio Penco; Loredana Vesci; Rosanna Foderà; Fabiana Fosca Ferrara; Mario Berardino Guglielmi; Paolo Carminati; Sabrina Dallavalle; Gabriella Morini; Lucio Merlini; Augusto Orlandi; Franco Zunino
Journal:  Mol Cancer Ther       Date:  2008-07       Impact factor: 6.261

View more
  1 in total

1.  Unnatural spirocyclic oxindole alkaloids biosynthesis in Uncaria guianensis.

Authors:  Adriana A Lopes; Bianca Chioca; Bruno Musquiari; Eduardo J Crevelin; Suzelei de C França; Maria Fatima das G Fernandes da Silva; Ana Maria S Pereira
Journal:  Sci Rep       Date:  2019-08-05       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.